Company: ABUS
Filing Date: 2025-08-06
Form Type: 8-K
Source: 0001171843-25-005076
Chunk: 1

Company: Arbutus Biopharma Corp
Filing Date: 2025-08-06
Form: 8-K
Item: Item 2.02
Chunk 1
---
 in the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 4, 2025.

The Company also entered into an indemnity agreement with Dr. Sawhney in connection with his appointment to the Board. The indemnity agreement is in substantially the same form as the indemnity agreement for all other directors of the Company, which was filed as Exhibit 10.1 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 27, 2025. No arrangement or understanding exists between and any other person pursuant to which was appointed as a director, and there are no transactions in which has an interest which would require disclosure under Item 404(a) of Regulation S-K of the Securities Act of 1933, as amended.

On August 6, 2025, the Company issued a press release announcing the transitions described under this Item 5.02. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference herein.